journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/28088513/an-immunogram-for-the-cancer-immunity-cycle-towards-personalized-immunotherapy-of-lung-cancer
#1
Takahiro Karasaki, Kazuhiro Nagayama, Hideki Kuwano, Jun-Ichi Nitadori, Masaaki Sato, Masaki Anraku, Akihiro Hosoi, Hirokazu Matsushita, Yasuyuki Morishita, Kosuke Kashiwabara, Masaki Takazawa, Osamu Ohara, Kazuhiro Kakimi, Jun Nakajima
INTRODUCTION: The interaction of immune cells and cancer cells shapes the immunosuppressive tumor microenvironment. For successful cancer immunotherapy, comprehensive knowledge of anti-tumor immunity as a dynamic spacio-temporal process is required for each individual patient. To this end, we developed an immunogram for the cancer-immunity cycle using next-generation sequencing. METHODS: Whole-exome sequencing and RNA-Seq was performed in 20 non-small cell lung cancer patients (12 adenocarcinoma, 7 squamous cell carcinoma, and 1 large cell neuroendocrine carcinoma)...
January 11, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28088512/ros1-fusions-rarely-overlap-with-other-oncogenic-drivers-in-non-small-cell-lung-cancer
#2
Jessica J Lin, Lauren L Ritterhouse, Siraj M Ali, Mark Bailey, Alexa B Schrock, Justin F Gainor, Lorin A Ferris, Mari Mino-Kenudson, Vincent A Miller, Anthony J Iafrate, Jochen K Lennerz, Alice T Shaw
INTRODUCTION: Chromosomal rearrangements involving the ROS proto-oncogene 1 receptor tyrosine kinase gene (ROS1) define a distinct molecular subset of non-small cell lung cancer (NSCLC) with sensitivity to ROS1 inhibitors. Recent reports have suggested a significant overlap between ROS1 fusions and other oncogenic driver alterations, including mutations in epidermal growth factor receptor (EGFR) and KRAS proto-oncogene (KRAS). METHODS: We identified patients at our institution with ROS1-rearranged NSCLC who had undergone testing for genetic alterations in additional oncogenes, including EGFR, KRAS, and anaplastic lymphoma kinase (ALK)...
January 11, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28088511/brief-report-egfr-l858m-l861q-cis-mutations-confer-selective-sensitivity-to-afatinib
#3
Jamie A Saxon, Lynette M Sholl, Pasi A Jänne
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with epidermal growth factor receptor (EGFR)-mutant lung cancers. However, the therapeutic efficacy of TKIs in patients with uncommon EGFR mutations remains unclear. METHODS: Next-generation sequencing was performed on a patient's lung adenocarcinoma tumor sample, revealing rare combined in cis (on the same allele) EGFR mutations. Stable Ba/F3 and NIH-3T3 cell lines harboring the mutations were established to investigate the effect of first, second, and third generation EGFR TKIs on cell proliferation by MTS assay and EGFR phosphorylation by Western blotting...
January 11, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28082103/the-role-of-extent-of-surgical-resection-and-lymph-node-assessment-for-clinical-stage-i-pulmonary-lepidic-adenocarcinoma-an-analysis-of-1-991-patients
#4
Morgan L Cox, Chi-Fu Jeffrey Yang, Paul J Speicher, Kevin L Anderson, Zachary W Fitch, Lin Gu, Robert Patrick Davis, Xiaofei Wang, Thomas A D'Amico, Matthew G Hartwig, David H Harpole, Mark F Berry
BACKGROUND: This study examined the association of extent of lung resection, pathologic nodal evaluation, and survival for patients with clinical stage I (cT1-2N0M0) adenocarcinoma with lepidic histology in the National Cancer Database (NCDB). METHODS: The association between extent of surgical resection and long-term survival for patients in the NCDB with clinical stage I lepidic adenocarcinoma who underwent lobectomy or sublobar resection was evaluated using Kaplan-Meier and Cox proportional hazards regression analyses...
January 7, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28034829/bap1-is-altered-by-copy-number-loss-mutation-and-or-loss-of-protein-expression-in-more-than-70-malignant-peritoneal-mesotheliomas
#5
Noémie Leblay, Frédéric Leprêtre, Nolwenn Le Stang, Amandine Gautier-Stein, Laurent Villeneuve, Sylvie Isaac, Denis Maillet, Françoise Galateau-Sallé, Céline Villenet, Shéhérazade Sebda, Alexandra Goracci, Graham Byrnes, James D McKay, Martin Figeac, Olivier Glehen, François-Noël Gilly, Matthieu Foll, Lynnette Fernandez-Cuesta, Marie Brevet
INTRODUCTION: Malignant mesothelioma is a deadly disease strongly associated with asbestos exposure. Peritoneal mesotheliomas account for 10% of all the cases. BAP1 is a deubiquitinating hydrolase that plays a key role in various cellular processes. Germ-line and somatic inactivation of BAP1 is frequent in pleural mesothelioma, however, little is known about its status in peritoneal mesothelioma. METHODS: Taking advantage of the extensive French national networks MESOPATH and RENAPE, we collected biological material and clinical and epidemiological data for 46 peritoneal mesothelioma patients...
December 27, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28017789/driven-by-mutations-the-predictive-value-of-mutation-subtype-in-egfr-mutated-non-small-cell-lung-cancer
#6
REVIEW
Emily Castellanos, Emily Feld, Leora Horn
Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease that includes over 200 distinct mutations. The implications of mutational subtype for both prognostic and predictive value are being increasingly understood. While the most common EGFR mutations-exon 19 deletion or L858R mutations-predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), it is now being recognized that outcomes may be improved in patients with exon 19 deletions. Additionally, 10% of patients will have an uncommon EGFR mutation, and response to EGFR TKI therapy is highly variable depending upon the mutation...
December 22, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28017788/association-of-serum-anti-gad-antibody-and-hla-haplotypes-with-type-1-diabetes-mellitus-triggered-by-nivolumab-in-patients-with-non-small-cell-lung-cancer
#7
Yuko Usui, Hibiki Udagawa, Shingo Matsumoto, Kenjiro Imai, Ken Ohashi, Masayuki Ishibashi, Keisuke Kirita, Shigeki Umemura, Kiyotaka Yoh, Seiji Niho, Keiichiro Osame, Koichi Goto
No abstract text is available yet for this article.
December 22, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28017787/randomized-phase-iii-trial-of-erlotinib-versus-docetaxel-in-patients-with-advanced-squamous-cell-non-small-cell-lung-cancer-failing-first-line-platinum-based-doublet-chemotherapy-stratified-by-veristrat-good-versus-veristrat-poor-the-european-thoracic-oncology
#8
Solange Peters, Rolf A Stahel, Urania Dafni, Santiago Ponce Aix, Bartomeu Massutí, Oliver Gautschi, Linda Coate, Ana López Martín, Robbert van Heemst, Thierry Berghmans, Peter Meldgaard, Manuel Cobo Dols, Javier Garde Noguera, Alessandra Curioni-Fontecedro, Daniel Rauch, Michael T Mark, Sinead Cuffe, Bonne Biesma, Arjen Mj van Henten, Óscar Juan Vidal, Ramón Palmero Sanchez, José Carlos Villa Guzmán, Ricardo Collado Martin, Sergio Peralta, Amelia Insa, Yvonne Summers, István Láng, Anne Horgan, Fortunato Ciardiello, Sander de Hosson, Remge Pieterman, Harry Jm Groen, Paul M van den Berg, Christoph C Zielinski, Yojena Chittazhathu Kurian Kuruvilla, Adriana Gasca-Ruchti, Marie Kassapian, Silvia Novello, Valter Torri, Zoi Tsourti, Vanesa Gregorc, Egbert F Smit
INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the Veristrat test in second-line therapy of NSCLC, classifying patients as either Veristrat "good" or "poor". EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely due to low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial...
December 22, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28017592/a-histologic-basis-for-the-efficacy-of-sbrt-to-the-lung
#9
Neil M Woody, Kevin L Stephans, Martin Andrews, Tingliang Zhuang, Priyanka Gopal, Ping Xia, Carol F Farver, Daniel P Raymond, Craig D Peacock, Joseph Cicenia, Chandana A Reddy, Gregory M M Videtic, Mohamed E Abazeed
PURPOSE: Stereotactic body radiation therapy (SBRT) is the standard of care for medically inoperable patients with early-stage NSCLC. However, NSCLC is composed of several histological subtypes and the impact of this heterogeneity on SBRT treatments has yet to be established. METHODS: We analyzed 740 patients with early-stage NSCLC treated definitively with SBRT from 2003 through 2015. We calculated cumulative incidence curves using the competing risk method and identified predictors of local failure using Fine and Gray regression...
December 20, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007630/improving-the-accuracy-of-mesothelioma-diagnosis-in-china
#10
Zhenying Guo, Michele Carbone, Xing Zhang, Dan Su, Wenyong Sun, Jianlin Lou, Zhibin Gao, Dichu Shao, Junqiang Chen, Gu Zhang, Jinlin Hu, Kaiyan Chen, Fang Wang, Harvey I Pass, Herbert Yu, Andrea Napolitano, Haining Yang, Weiming Mao
BACKGROUND: In the Western World malignant mesothelioma (MM) is most prevalent in the pleura of older males professionally exposed to asbestos. Information about MM from rapidly industrializing countries, such as China, is minimal. There is concern that a proportion of MM diagnoses in China may be incorrect because most Chinese physicians do not have experience diagnosing this rare cancer. We recently reported an unusual high incidence of peritoneal MM among Eastern Chinese female patients...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007629/alk-rearrangement-detected-in-a-focus-of-pulmonary-atypical-adenomatous-hyperplasia
#11
Filippo Lococo, Alessandra Bisagni, Maria Cecilia Mengoli, Alberto Cavazza, Giulio Rossi
No abstract text is available yet for this article.
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007628/a-dose-escalation-clinical-trial-of-single-fraction-carbon-ion-radiotherapy-for-peripheral-stage-i-non-small-cell-lung-cancer
#12
Naoyoshi Yamamoto, Tadaaki Miyamoto, Mio Nakajima, Masataka Karube, Kazuhiko Hayashi, Hiroshi Tsuji, Hirohiko Tsujii, Tadashi Kamada, Takehiko Fujisawa
PURPOSE: To report initial results ofadose escalation trial of single-fraction carbon-ion radiotherapy (CIRT) for peripheralstage I non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Between April, 2003 and February, 2012, 218 patients were treated. The total dose was raised from 28to 50Gy RBE. The patients were 157 males and 61 females with a median age of 75 years. The tumors were 123 T1 and 95 T2. One hundred thirty-four of these patients (61.5%) were medically inoperable...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007627/clinical-outcome-of-alk-positive-non-small-cell-lung-cancer-nsclc-patients-with-de-novo-egfr-or-kras-co-mutations-receiving-tyrosine-kinase-inhibitors-tki
#13
Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Früh Martin
BACKGROUND: Non-small cell lung cancer (NSCLC) with de novo anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) or Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations co-occur very rarely. Outcomes with tyrosine kinase inhibitors (TKIs) in these patients (pts) are poorly understood. METHODS: Outcomes of pts with metastatic NSCLC de novo co- alterations of ALK/EGFR or ALK/KRAS detected by FISH (ALK) and sequencing (EGFR/KRAS) from six Swiss centres were analysed...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007626/risk-of-treatment-related-toxicities-from-egfr-tyrosine-kinase-inhibitors-a-meta-analysis-of-clinical-trials-of-gefitinib-erlotinib-and-afatinib-in-advanced-egfr-mutated-non-small-cell-lung-cancer
#14
Pei Ni Ding, Sarah J Lord, Val Gebski, Matthew Links, Victoria Bray, Richard J Gralla, James Chih-Hsin Yang, Chee Khoon Lee
BACKGROUND: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC). Estimating differences in toxicity between these EGFR-TKIs is important for personalizing treatment. METHODS: We performed a meta-analysis of randomized trials that compared EGFR-TKI against chemotherapy or placebo. We extracted data from the EGFR-TKI arm for indirect comparisons to estimate the relative risk of toxic death, grade 3-4 (G3/4) adverse events (AEs) and treatment discontinuation due to AE for each EGFR-TKI...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007625/size-and-growth-assessment-of-pulmonary-nodules-consequences-of-the-rounding
#15
Kunwei Li, Rowena Yip, Ricardo Avila, Claudia I Henschke, David F Yankelevitz
PURPOSE: To understand the effect of rounding nodule size measurements on the frequency of positive results in the lung cancer screening setting. METHODS: Four methods for determining nodule size were compared, including rounding each individual length and width measurement and also rounding the overall average. These were applied to the I-ELCAP database where we determined the frequency of a positive result using standard size thresholds of 6.0 mm on baseline screening and 3...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007624/capture-based-targeted-ultra-deep-sequencing-in-paired-tissue-and-plasma-samples-demonstrates-differential-subclonal-ctdna-releasing-capability-in-advanced-lung-cancer
#16
Xiaowei Mao, Zhou Zhang, Xiaoxuan Zheng, Fangfang Xie, Feidie Duan, Liyan Jiang, Shannon Chuai, Han Han-Zhang, Baohui Han, Jiayuan Sun
INTRODUCTION: Circulating tumor DNA (ctDNA), representing an unbiased way to assess tumor genetic profile non-invasively, facilitates studying intratumor heterogeneity. Although intratumor heterogeneity has been elucidated substantially in a few cancer types, including non-small cell lung cancer (NSCLC), how it influences the ability of tumor cells harboring different genetic abnormalities in releasing their DNA remains elusive. We designed a capture-based panel targeting NSCLC to detect and quantify genetic alterations from plasma using deep sequencing...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28007623/small-cell-lung-cancer-exhibits-frequent-inactivating-mutations-in-the-histone-methyltransferase-kmt2d-mll2-calgb-151111-alliance
#17
Arnaud Augert, Qing Zhang, Breanna Bates, Min Cui, Xiaofei Wang, Gary Wildey, Afshin Dowlati, David MacPherson
INTRODUCTION: Small cell lung carcinoma (SCLC) is a lethal neuroendocrine tumor type, highly prone to metastasis. There is an urgency to understand the mutated genes that promote SCLC, as there are no approved targeted therapies yet available. SCLC is rarely resected, limiting the number of samples available for genomic analyses of somatic mutations. METHODS: To identify potential driver mutations in human SCLC we sequenced the whole exomes of 18 primary SCLCs and 7 cell lines along with matched normal controls...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27998793/the-use-of-immunohistochemistry-improves-the-diagnosis-of-small-cell-lung-cancer-and-its-differential-diagnosis-an-international-reproducibility-study-in-a-demanding-set-of-cases
#18
Erik Thunnissen, Alain C Borczuk, Douglas B Flieder, Birgit Witte, Mary Beth B Beasley, Jin-Haeng Chung, Sanja Dacic, Sylvie Lantuejoul, Prudence A Russell, Michael den Bakker, Johan Botling, Elisabeth Brambilla, Erienne de Cuba, Kim Geisinger, Kenzo Hiroshima, Alberto Marchevsky, Yuko Minami, Andre Moreira, Andrew G Nicholson, Akihiko Yoshida, Ming-Sound Tsao, Arne Warth, Edwina Duhig, Gang Chen, Yoshihiro Matsuno, William D Travis, Kelly Butnor, Wendy Cooper, Mari Mino-Kenudson, Noriko Motoi, Claudia Poleri, Giuseppe Pelosi, Keith Kerr, Seena C Aisner, Yuichi Ishikawa, Reinhard H Buettner, Naoto Keino, Yasushi Yatabe, Masayuki Noguchi
INTRODUCTION: The current World Health Organization (WHO) classification of lung cancer states that a diagnosis of small cell lung carcinoma (SCLC) can be reliably made on routine histological and cytological grounds, but immunohistochemistry may be required, particularly i) in cases where histologic features are equivocal and ii) in cases where the pathologist wants to increase confidence in diagnosis.. However, reproducibility studies on hematoxylin and eosin-stained slides (H&E) alone for SCLC versus large cell neuroendocrine carcinoma (LCNEC) have shown pairwise kappa scores ranging from 0...
December 17, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27923715/imaging-phenotyping-using-radiomics-to-predict-micropapillary-pattern-within-lung-adenocarcinoma
#19
So Hee Song, Hyunjin Park, Geewon Lee, Ho Yun Lee, Insuk Sohn, Hye Seung Kim, Seung Hak Lee, Ji Yun Jeong, Jhingook Kim, Kyung Soo Lee, Young Mog Shim
INTRODUCTION: Lung adenocarcinoma (ADC) with micropapillary pattern have been reported to have a poor prognosis. However, few studies have reported on the imaging-based identification of micropapillary component, which were all subjective studies dealing with qualitative CT variables. We aimed to explore imaging phenotyping using a radiomics approach for predicting micropapillary pattern within lung ADC METHODS: We enrolled 339 patients who underwent complete resection for lung ADC. Histologic subtypes and grades of the ADCs were classified...
December 3, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27923714/brief-report-acquired-braf-v600e-mutation-as-resistant-mechanism-after-treatment-with-osimertinib
#20
Chao-Chi Ho, Wei-Yu Liao, Chih-An Lin, Jin-Yuan Shih, Chong-Jen Yu, James Chih-Hsin Yang
INTRODUCTION: AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been used. Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified. It is unclear, however, whether the bypass pathway is also a resistant mechanism in patients after osimertinib treatment. METHODS: Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib...
December 3, 2016: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"